October 19, 2015 | Israeli bio-medical company Advanced Inhalation Therapies (AIT) has filled for initial public offering on the Nasdaq. The Rehovot-based company is expecting to raise up to $36 million, according to Renaissance Capital. Founded in 2011 and run by CEO and Co-Founder, Amir Avniel, AIT has cystic fibrosis and bronchiolitis drugs in Phase IIb clinical trials. Avniel was previously CEO of Rosetta Genomics, another Israeli bio-medical company, which he led to a Nasdaq IPO.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments